|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fatty liver disease,an emerging etiology of hepatocellular carcinoma in Argentina显示文摘AIM To investigate any changing trends in the etiologies of hepatocellular carcinoma(HCC) in Argentina during the last years. METHODS A longitudinal cohort study was conducted by 14 regional hospitals starting in 2009 through 2016. All adult patients with newly diagnosed HCC either with pathology or imaging criteria were included. Patients were classified as presenting non-alcoholic fatty liver disease(NAFLD) either by histology or clinically, provided that all other etiologies of liver disease were ruled out, fatty liver was present on abdominal ultrasound and alcohol consumption was excluded. Complete follow-up was assessed in all included subjects since the date of HCC diagnosis until death or last medical visit.RESULTS A total of 708 consecutive adults with HCC were included. Six out of 14 hospitals were liver transplant centers(n = 484). The prevalence of diabetes mellitus was 27.7%. Overall, HCV was the main cause of liver disease related with HCC(37%) including cirrhotic and non-cirrhotic patients, followed by alcoholic liver disease 20.8%, NAFLD 11.4%, cryptogenic 9.6%, HBV 5.4% infection, cholestatic disease and autoimmune hepatitis 2.2%, and other causes 9.9%. A 6-fold increase in the percentage corresponding to NAFLDHCC was detected when the starting year, i.e., 2009 was compared to the last one, i.e., 2015(4.3% vs 25.6%; P < 0.0001). Accordingly, a higher prevalence of diabetes mellitus was present in NAFLD-HCC group 61.7% when compared to other than NAFLD-HCC 23.3%(P < 0.0001). Lower median AFP values at HCC diagnosis were observed between NAFLD-HCC and non-NAFLD groups(6.6 ng/m L vs 26 ng/m L; P = 0.02). Neither NAFLD nor other HCC etiologies were associated with higher mortality.CONCLUSION The growing incidence of NAFLD-HCC documented in the United States and Europe is also observed in Argentina, a confirmation with important Public Health implications. | Federico Pinero Josefina Pages Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Manuel Cobos Carlos Rosales Gustavo Romero Lucas McCormack Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2018 | World Journal of Hepatology2018，10，1： | 4 |
| 2 | Applications of genomics in NSCLC显示文摘 | Rosell R Cobo M Isla D | | 0，，2： | 2 |
| 3 | Two-microphone multi-speaker localization based on a laplacian mixture model显示文摘 | Cobos M Lopez J J and Martinez D | 2010 | Digital Signal Processing2010，21，1： | 1 |
| 4 | In vitro antibradykinin activity of Aloe barbadensis gel 显示文摘 | Bautista - Perez R Segura - Cobos D Vazquez - Cruz B | 2004 | Journal of Ethnophar- macology2004，93，1： | 1 |
| 5 | Synthesis of higher alcohols with cobalt and copper based modelcatalysts: effect of the alkaline metals显示文摘 | Aquino A D Cobo A J G | 2001 | Catal Today2001，65，： | 1 |
| 6 | Reaction kinetics and mechanisms of neonicotinoid pesticides with sulfate radicals显示文摘 | DELL'ARCIPRETE M L COBOS C J MARTIRE D O | 2011 | New Journal of Chemistry2011，35，3： | 1 |
| 7 | ERCC1 mRNA-based randomized phase Ⅲ trial of docetaxel(doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage Ⅳ non-small-cell lung cancer (NSCLC) patients(p)显示文摘 | Rosell R Cobo M Isla D | | 0，，1： | 1 |
| 8 | Customizing cisplatin based on quantitative excision repair cross-complementing Ⅰ mRNA expres- sion:aphase Ⅲ trial in non-small-cell lung cancer显示文摘 | Cobo M Isla D Massuti B | 2007 | J Clin On- col2007，25，19： | 1 |
| 9 | ERCC1 mRNA-based randomized phase Ⅲ trial of docetaxel doublets with cisplatin or gemcitabine in stage Ⅳ non-small-cell lung cancer ( NSCLC ) patients显示文摘 | Rosell R Cobo M Isla D | 2005 | Proc Am Soc Clin Oncol2005，24，： | 1 |
| 10 | ERCC1 mRNA-based ran- domized phase Ⅲ trial of docetaxel (doc) doublets with cisplatin (cis) or gemeitabine (gem) in stagelV non small-cell Lung canc-er (N SCLC) patients 显示文摘 | Rosell R Cobo M Isla D | 2005 | J ClinOncol2005，23，1： | 1 |
| 11 | Hiarmacogenomics andgemcitabine 显示文摘 | Rosell R Cobo M Isla D | 2006 | Arm Oncol2006，17，5： | 1 |
| 12 | Customizing cisplatin based on quantitative excision repair cross-complementing1 mRNA expression:a phase Ⅲ trial in non-small-cell lung cancer显示文摘 | Cobo M Isla D Massuti B | 2007 | J Clin Oncol2007，25，19： | 1 |
| 13 | Decomposition and nutrient release by green manures in a tropical hillside agroecosystem 显示文摘 | Cobo J G Barrios E Kass D C L | 2002 | Plant Soil2002，240，2： | 1 |
| 14 | Pharmacogenomics and gemcitabine显示文摘 | Rosell R Cobo M Isla D | | 0，，5： | 1 |
| 15 | ERCC1 mRNA-based randomized phase Ⅲ trial of docetaxel doublets with cisplatin or gemcitabine in stage Ⅳ non-smal cell lung cancer (NSCLC) patients显示文摘 | ROSELL R COBO M ISLA D | 2005 | Proc Am Soc Clin Oncol2005，24，： | 1 |
| 16 | Pharmacogenomics and gemcitabine 显示文摘 | Rosell R Cobo M Isla D | 2006 | Annals of Oncology2006，17，： | 1 |
| 17 | Customizing cisplatin based on quantitativeexcisionrepaircross-complementing 1 mRNA expression:a phase Ⅲ trial in non-small-cell lung cancer显示文摘 | Cobo M Isla D Massuti B | 2007 | J Clin Onco12007，25，19： | 1 |
| 18 | ERCC1 mRNA- based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non - small - cell lung cancer (NSCLC) patients (p) 显示文摘 | Rosell R Cobo M Isla D | 2005 | J Clin Oncol2005，23，16： | 1 |
| 19 | Successful therapeutic use of rituximab in refractory membranous glomerulonephritis 显示文摘 | Cobo M Hemandez D Rodriguez C | 2006 | Clin Nephrol2006，66，1： | 1 |
| 20 | Lowering bronchoaspiration rate in an acute stroke unit by means of a 2 volume/3 texture dysphagia screening test with pulsioximetry 显示文摘 | Cocho D Sagales M Cobo M | 2015 | Neurologia (Barcelona Spain)2015，4，14： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员